Stockreport

Ocugen (OCGN) Reveals OCU410 Clinical Trial Data [Yahoo! Finance]

Ocugen, Inc.  (OCGN) 
PDF On March 24, Ocugen Inc. (NASDAQ:OCGN) announced 12-month data from the Phase 2 ArMaDa clinical trial evaluating OCU410, its modifier gene therapy for geographic atroph [Read more]